# SLE Digital Twin Living Requirements Specification (SLE-DT LRS)

## Revision Status
Integrated Literature Reviews
1. SLE DEG Bioinformatics Review.
2. AI, Biomarkers, and Precision Rheumatology Review.
3. Digital Twins and the Metaverse in Healthcare Review.
4. AI Autoimmune Research Trends (2025 Bibliometric Analysis).
5. AI for Systemic Lupus Erythematosus Personalized Treatment.
6. The Role of Health Information Technology in the Control and Management of SLE.

---

## Canonical Thesis Direction
### Selected MVP Architecture
Transcriptomics-First + Molecular-Endotype-Aware Healthcare Digital Twin.

### MVP Scope Decision
The MVP remains focused on:
- Systemic Lupus Erythematosus (SLE).
- Transcriptomic data.
- Healthy-vs-disease immune-state modeling.
- Molecular endotype discovery.
- Immune-tolerance restoration.
- Explainable pathway and target prioritization.

The new literature reinforces that SLE heterogeneity is a primary challenge and that patient grouping and stratification are essential requirements. Therefore, molecular endotyping remains the preferred MVP strategy. 

---

## Research Objective Representation
The Digital Twin represents:
- Patient immune state.
- Disease-state deviation from health.
- Molecular endotypes.
- Active pathways.
- Candidate restoration opportunities.
- Patient-specific biological hypotheses.

It does NOT represent:
- A treatment recommendation engine.
- A clinical decision support product.
- A telemedicine platform.
- A patient-management application.

---

## Executive Thesis Objective
Develop an explainable Digital Twin that models patient-specific immune dysregulation, identifies disease-driving pathways, stratifies patients into biologically meaningful subgroups, simulates restoration of immune tolerance, and generates testable therapeutic hypotheses.

---

## MVP Requirements
### Included
- Public GEO datasets.
- Healthy control cohorts.
- Differential expression analysis.
- Pathway enrichment analysis.
- PPI analysis.
- Molecular endotype discovery.
- Healthy reference twin.
- Patient twin.
- Virtual perturbation engine.
- Explainable target ranking.
- Technical validation.
- Biological validation.

### Out of Scope
- Clinical deployment.
- Treatment recommendation.
- Real-time monitoring.
- Telemedicine implementation.
- Wearable integration.
- Multi-omics integration.
- EHR integration.

---

## SLE Heterogeneity Requirements (NEW)
The Health IT review reinforces that SLE presents with highly variable manifestations and disease trajectories.

Requirements:
- The architecture must assume patient heterogeneity.
- Patient grouping must be performed prior to major downstream analyses whenever feasible.
- Disease modeling should not assume a single dominant disease mechanism across all patients.
- Validation should assess whether prioritized pathways remain stable within identified endotypes.

---

## Molecular Endotype Requirements
Disease subtyping is a foundational requirement.

### Required Signals
- Gene-expression signatures.
- Pathway activation profiles.
- Interferon activity.
- Immune-state signatures.
- B-cell-related signatures.

### Future Endotype Layers
Potential future grouping strategies identified across literature:
- Biological markers.
- Organ involvement.
- Disease severity.
- Symptom clusters.
- Treatment-response patterns.

Currently, biological and transcriptomic stratification remains the preferred MVP approach because it is directly supported by available data.

---

## Scientific Foundation
### Core Biological Themes
- Immune tolerance restoration.
- Molecular heterogeneity.
- Patient stratification.
- Explainable AI.

### Key Disease Mechanism Categories
- Neutrophil biology.
- Interferon biology.
- B-cell biology.
- T-cell regulatory biology.

---

## Data Strategy
### Core Datasets
- GSE162828.
- GSE169080.

### First-Class Requirement: Healthy Controls
The literature repeatedly identifies healthy-control cohorts as critical for meaningful disease-state comparison.

### Dataset Documentation Requirements
Capture when available:
- Age.
- Sex.
- Ethnicity.
- Disease subtype.
- Organ involvement.
- Clinical metadata.
- Treatment history.

### Data Standardization Requirements (NEW)
Because SLE data may originate from multiple specialties and diagnostic modalities:
- Data normalization shall be documented.
- Batch-effect correction shall be documented.
- Missing-data handling shall be documented.
- Feature provenance shall be documented.

---

## Clinical Context Layer (NEW)
The Health IT review highlights that SLE management often involves:
- Rheumatology.
- Nephrology.
- Dermatology.
- Neurology.
- Hematology.

Future Digital Twin evolution should support incorporation of disease information from multiple clinical domains.

This remains outside the MVP.

---

## Future AI Capability Roadmap
### Single-Cell Extensions
- scRNA-seq integration.
- Automated cell-state annotation.
- Cell-state discovery.

### Multi-Modal Patient Monitoring
Future phases may investigate:
- Clinical laboratory data.
- Patient-reported outcomes.
- Digital biomarkers.
- Wearable data.

This direction is supported by future opportunities identified in the Health IT review.

---

## Validation Framework
### Technical Validation
- Reproducibility.
- Stability.
- Cross-dataset consistency.
- Sensitivity analysis.

### Biological Validation
Recover:
- Neutrophil pathways.
- Interferon pathways.
- B-cell signatures.
- Published hub genes.

### Stratification Validation (NEW)
Assess:
- Endotype stability.
- Cohort reproducibility.
- Within-endotype pathway consistency.

---

## Open Research Questions
Unanswered by currently reviewed literature:

1. Can deep learning outperform DEG-to-PPI workflows?
2. Which hub genes remain important under graph-learning approaches?
3. Can ML recover biologically meaningful genes removed by traditional thresholds?
4. How accurately can transcriptomics alone predict therapeutic targets?
5. Are public longitudinal SLE cohorts available?
6. How should production Digital Twins implement drift monitoring?
7. Can subtype-specific twins outperform generalized twins?
8. How should wearable-derived biomarkers be integrated?
9. Which public datasets contain both molecular and digital-health data?
10. What minimum biomarker set is necessary for a clinically useful lupus twin?
11. Has a fully customizable patient-specific SLE Digital Twin already been demonstrated?
12. Which healthcare DT category best aligns with lupus research goals?
13. Would an organ-specific lupus DT provide sufficient MVP value?
14. Should architecture evolve toward system-wide or organ-specific twins?
15. Which lupus target organ provides highest-value future organ-level twin?
16. Are existing lupus organ simulation platforms available?
17. Which biological, clinical, behavioral, and environmental variables are essential?
18. Are datasets from B-cell-targeting therapy studies publicly available?
19. Which SLE subtype is the most achievable MVP target?
20. Which sequencing and genome-analysis tools are most established in SLE research?
21. Can multi-omics AI models reliably predict individual treatment response?
22. Can digital-health platforms generate sufficiently standardized datasets for predictive AI?
23. What combination of clinical, laboratory, and patient-reported variables provides the strongest predictive value?
24. Should future ML grouping strategies rely primarily on biological markers, symptom clusters, severity, organ involvement, or treatment history?

### Questions Partially Addressed
- SLE heterogeneity is a major modeling challenge.
- Patient stratification is necessary.
- Biological grouping appears more aligned with the current MVP than symptom-only grouping.

---

## Expected Thesis Contributions
- Explainable SLE Digital Twin architecture.
- Molecular-endotype-aware disease modeling.
- Immune-tolerance restoration framework.
- Heterogeneity-aware patient stratification.
- Validation-oriented healthcare Digital Twin methodology.
- Reproducible research platform.

---

## References (IEEE)
[1] Zhao et al., Identification of Biomarkers and Pathways in SLE.
[2] GEO GSE162828.
[3] GEO GSE169080.
[4] STRING.
[5] Cytoscape.
[6] limma.
[7] AI, Biomarkers, and Precision Medicine in AIRDs.
[8] Digital Twins and the Metaverse in Healthcare and Industry.
[9] AI and Autoimmune Disease Research Trends (2025).
[10] AI for Systemic Lupus Erythematosus Personalized Treatment.
[11] The Role of Health Information Technology in the Control and Management of Systemic Lupus Erythematosus.
